11 June, 2025
The latest instalment of the ERS Interactive Education video series is now available to watch on the ERS Respiratory Channel.
‘IL-5 in severe asthma: halting progression, achieving remission’ aims to bridge gaps in knowledge by linking IL-5 biology to clinical outcomes through case-based learning led by experts in the field.
Severe eosinophilic asthma, driven by IL-5-mediated eosinophilic inflammation, airway remodelling, and mucus plugging, remains a clinical challenge due to persistent gaps in diagnosis and management. Clinicians often struggle to differentiate adult-onset asthma from COPD, underutilise biomarkers, and delay IL-5 biologics despite their proven efficacy in reducing exacerbations and halting progression. Overreliance on steroids and misconceptions about remission – prioritising symptom control over structural stability – further hinder care.
The experts – Dr Hitasha Rupani, Prof. Marek Lommatzsch and Prof. Arnaud Bourdin – will lead participants through this topic to enable them to:
- Explain how IL-5-driven eosinophilic inflammation contributes to airway remodeling, mucus plugging, and functional decline in severe asthma.
- Differentiate adult-onset eosinophilic asthma from COPD using clinical history, biomarkers, and imaging.
- Evaluate the role of IL-5-targeted biologics in halting disease progression by reducing exacerbations and preserving lung function.
- Apply strategies to achieve remission through biomarker-guided therapy and steroid-sparing approaches.
Watch the video on the ERS Respiratory Channel.
Access all ERS Interactive Education videos.